Blood cancer mutations may trigger Alzheimer’s
Mutations typically linked to blood cancer also appear to play a role in Alzheimer’s disease. That unexpected finding could reshape how we think about dementia risk.
Researchers found that certain mutations in blood cells can cause brain immune cells known as microglia to become overactive. That overactivation triggers a strong inflammatory response in the brain, which may contribute to the development of Alzheimer’s disease. The discovery points to a genetic bridge between the bloodstream and the brain that was not previously recognised.
An unexpected genetic link
The mutations in question belong to a category found in ageing people at elevated risk for blood cancer. This phenomenon is called clonal haematopoiesis, the process by which a mutated blood stem cell gradually produces a growing population of genetically identical descendants. As we age, such mutations accumulate. Until now, attention focused mainly on their cancer risk.
That these mutations might also influence the brain is a new observation. The researchers suggest that mutant blood cells entering the brain may mount a more aggressive inflammatory response than normal microglia. Whether this actually accelerates Alzheimer’s progression in humans has not yet been proven, the study provides a mechanistic clue, not clinical evidence.
A path toward blood-based screening
The finding does open an intriguing possibility. Clonal haematopoiesis can be detected with a standard blood test. If the link with Alzheimer’s is confirmed, that could mean a routine blood draw might one day inform dementia risk. Early detection of Alzheimer’s remains one of medicine’s most pressing unsolved problems.
The researchers also raise the possibility that drugs already used in oncology, treatments that target these blood mutations, could be repurposed to reduce brain inflammation. From a longevity perspective, this is worth noting: age-related mutations in blood cells may shape long-term brain health. But these remain speculative steps, and further research is needed before any clinical conclusions can be drawn.